UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 26, 2006
VERTEX PHARMACEUTICALS INCORPORATED
(Exact name of registrant as specified in its charter)
|
MASSACHUSETTS |
|
000-19319 |
|
04-3039129 |
130
Waverly Street
Cambridge, Massachusetts 02139
(Address of principal executive offices) (Zip Code)
(617)
444-6100
Registrant’s telephone number, including area code:
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01. Entry into a Material Definitive Agreement.
On June 26, 2006, Vertex Pharmaceuticals Incorporated and Merck & Co., Inc. agreed to extend the Research Program Term under the Exclusive Research Collaboration, License and Commercialization Agreement, dated as of June 21, 2004 (the “Collaboration Agreement”), between the parties. As a result of this extension, the Research Program Term under the Collaboration Agreement will expire on September 21, 2006.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
VERTEX PHARMACEUTICALS |
|
|
|
|
(Registrant) |
|
|
|
|
|
Date: June 26, 2006 |
|
/s/ Kenneth S. Boger |
|
|
|
Kenneth S. Boger |
2